News
LTRN
9.78
-2.49%
-0.25
Weekly Report: what happened at LTRN last week (0318-0322)?
Weekly Report · 3d ago
Lantern Pharma’s Triple Threat: Inflation, Global Tensions, and Pandemic Impacts Jeopardize Financial Health
TipRanks · 03/20 06:02
BUZZ-U.S. STOCKS ON THE MOVE-US energy sector, Avis, NuScale
The tech-laden Nasdaq dipped on Tuesday with chip stocks falling to more than two-week lows. The Dow Jones Industrial Average was up 0.67% as focus turned to the Federal Reserve's policy meeting. The top three S&P 500 percentage gainers were International Paper Co, up 10%.
Reuters · 03/19 17:48
12 Health Care Stocks Moving In Tuesday's Intraday Session
Ontrak (NASDAQ:OTRK) shares increased by 97.6% to $0.38 during Tuesday's regular session. Fusion Pharmaceuticals stock moved upwards by 97%. SCWorx stock rose 70.74% and Enliven Therapeutics stock increased by 29.19%. Acutus Medical stock declined by 26.5% during the session.
Benzinga · 03/19 17:31
OTRK, STRC and APM among mid-day movers
On the Move OTRK, STRC and APM among mid-day movers. Fusion Pharmaceuticals (FUSN) and Ontrak (OTRK) are among the Gainers. NuScale Power Corporation (SMR) is among the losers.
Seeking Alpha · 03/19 16:48
BUZZ-U.S. STOCKS ON THE MOVE-National Cinemedia, Crinetics Pharma, Nordstrom
The S&P 500 and the Nasdaq fell on Tuesday with most megacap and chip stocks weakening. The Dow Jones Industrial Average was up 0.56%. National Cinemedia, Crinetics Pharma, Nordstrom were up. The top three Nasdaq percentage gainers were International Paper, Boeing and Boeing.
Reuters · 03/19 16:05
Graphite Bio, SCWorx, Acurx Pharmaceuticals among healthcare movers
Graphite Bio, SCWorx, Acurx Pharmaceuticals among healthcare movers. S&P 500 Health Care Sector -0.02% to 1689.96. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index is +0.01% to 1378.25.
Seeking Alpha · 03/19 14:00
H.C. Wainwright Reaffirms Their Hold Rating on Lantern Pharma (LTRN)
H.C. Wainwright analyst Emily Bodnar maintained a Hold rating on Lantern Pharma. The company’s shares closed yesterday at $9.96. Bodnar covers the Healthcare sector and has an average return of 13.8%. Lantern Pharma is a clinical-stage biotechnology company. The analyst consensus on the company is currently a Hold.
TipRanks · 03/19 10:29
LTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023
Lanner Pharma reported earnings per share of -39 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. Lantern Pharma reported results above the analyst estimate for -40 cents per share. The stock is down 2% today.
Investorplace · 03/19 00:53
Lantern Pharma Inc reports results for the quarter ended in December - Earnings Summary
Lantern Pharma Inc reports results for the quarter ended in December. Lantern Pharma Inc shares had risen by 103.3% this quarter. The company reported a quarterly adjusted loss of 39 cents per share. The mean expectation of two analysts was for a loss of 40 cents.
Reuters · 03/18 21:01
Recap: Lantern Pharma Q4 Earnings
Lantern Pharma reported its Q4 earnings on March 18. Lantern Pharma beat estimates by 3.0%. The company's revenue was down $0 from the same period last year. Last quarter the company beat on EPS by $0.16 and the share price rose 33.0% the next day.
Benzinga · 03/18 20:30
Lantern Pharma Q4 2023 GAAP EPS $(0.39) Beats $(0.48) Estimate
Benzinga · 03/18 20:26
Lantern Pharma Announces Fiscal Year and Q4 Results Webinar
TipRanks · 03/18 20:25
Lantern Pharma GAAP EPS of -$0.39 beats by $0.01
Lantern Pharma Inc. Q4 GAAP EPS of -$0.39 beats by $0.01. Cash, cash equivalents, and marketable securities were approximately $41.3 million as of December 31, 2023. Lantern Pharma's Q4 revenue was $8.2 million.
Seeking Alpha · 03/18 20:08
Press Release: Lantern Pharma Reports Fourth -2-
Lantern formed a wholly-owned subsidiary, Starlight Therapeutics, for the clinical development of drug LP-184's central nervous system and brain cancer indications. The market potential for the drug is estimated to be $4.5 billion to $5 billion. The company is developing a novel, potent, cryptophycin-based ADC.
Dow Jones · 03/18 20:02
Press Release: Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
Lantern Pharma reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights. Multiple clinical trials across three AI-guided drug candidates are active. The company has three drug candidates in active clinical trials for cancer indications. Lantern Pharma is developing targeted and transformative cancer therapies using its AI and machine learning platform.
Dow Jones · 03/18 20:02
After-Hours Earnings Report for March 18, 2024 : STNE, DLO, ALPN, YY, BTBT, CMTL, LTRN, EYEN, RAIL, RFIL, PRSO
NASDAQ · 03/18 18:00
Weekly Report: what happened at LTRN last week (0311-0315)?
Weekly Report · 03/18 11:40
Earnings Scheduled For March 18, 2024
Niu Techs (NASDAQ:NIU) is expected to report earnings for its fourth quarter. Embraer is estimated to report quarterly earnings at $0.53 per share on revenue of $2.00 billion. Companies Reporting Before The Bell include System1 and Nano Labs.
Benzinga · 03/18 09:57
Notable earnings after Monday's close
Major earnings expected after the bell on Monday include: StoneCo Ltd. And JOYY. Other major earnings slated for release after Monday's close include: ALPN, AUGX, RAIL, ZEPP, STNE, DLO. For the full earnings season calendar, click here.
Seeking Alpha · 03/17 21:35
More
Webull provides a variety of real-time LTRN stock news. You can receive the latest news about Lantern Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About LTRN
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 60 billion oncology-focused data points and a library of over 200 advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.